According to research, melanoma patients may live longer if they take beta blockers, a class of drugs used to manage abnormal heart rhythm and prevent heart attacks.
Researchers at Penn State found that melanoma patients who received immunotherapy while taking a specific type of beta blocker lived longer than patients who received immunotherapy alone.
In a follow-up experiment with mice, the researchers saw the same results.
Dr. Todd Schell, professor of microbiology and immunology at Penn State College of Medicine, said that because beta blockers are already widely available, the findings could indicate a simple way for physicians to better treat their patients.
“The type of beta blocker we found to be effective against melanoma - pan beta blockers - was actually the least prescribed,” Schell said. “Most patients are either prescribed beta 1 selective blockers or are not taking beta blockers at all. This means there’s a large population of patients who may be eligible to take pan beta blockers while being treated with immunotherapy. And because beta blockers are already FDA approved, it’s something we know is safe and can be very quickly implemented in patient care.”
Patients with metastatic melanoma, or melanoma that has spread to other parts of the body, often have a poor prognosis, and while some forms of immunotherapy - treatments that boost the body’s immune system to fight disease - are promising, response rates are less than 35 %.
Previous research has shown that physiological stress prevents the immune system from fighting tumors effectively, while lower stress boosts the benefits of anti-cancer treatments. The researchers were curious about whether lowering stress with beta blockers would improve outcomes in patients treated with immunotherapies.
“Beta blockers slow your heart rhythm, but they can also affect immune cells and improve immune function,” Schell said.
“We wanted to see if there would be a correlation between the beta blockers patients were taking for another condition and their response to immunotherapy. For metastatic melanoma, there are currently three different types of immunotherapy approved for use, and we specifically looked at that population of people.”
In studies developed by Dr. Kathleen Kokolus, the researchers analyzed data from 195 metastatic melanoma patients who were treated with immunotherapy between 2000 and 2015, 62 of which were also taking beta blockers.
They compared survival between the patients taking beta 1-selective blockers, pan beta blockers and no beta blockers. While there was little difference in how long patients taking beta 1-selective blockers or no beta blockers lived, the results indicate that patients taking pan beta blockers lived significantly longer than the others.
Five years after immunotherapy, about 70 % of patients receiving pan beta blockers were still alive, versus about 25 % of those taking beta 1-selective blockers or no beta blockers at all.
To help explain the results, the team performed a parallel experiment in mice with melanoma. They treated the mice with immunotherapy and with or without the pan beta blocker propranolol.
The researchers found that the propranolol significantly delayed tumor growth and increased survival when combined with immunotherapy.
Dr. Joseph Drabick, physician and professor of medicine at Penn State College of Medicine, said the results suggest that reducing physiological stress with beta blockers can help improve the effectiveness of immunotherapy and survival for melanoma patients.
“These new immunotherapies are great, but they don’t work for everyone,” Drabick said. “So how can we make these treatments better? We saw that for patients taking pan beta blockers, there was a dramatic improvement in survival, and we were able to duplicate these findings in mice and see the exact same phenomenon.”Drabick also said the study was a good example of the benefits of finding new uses for drugs that have been around awhile.
“The benefit of this is that beta blockers already have a long history of safety in people, and they’re cheap and generic,” Drabick said. “And now they have the potential to augment some of these newer immunotherapy drugs to help people with cancer.”